XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
KUAISHOU-W
01024
BIDU-SW
09888
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 26.64%8.09B | 34.24%4.63B | 13.94%1.98B | 6.82%8.42B | 10.29%6.38B | -2.51%3.45B | 2.45%1.74B | 14.96%7.89B | 7.94%5.79B | 1.41%3.54B |
Operating income | 26.64%8.09B | 34.24%4.63B | 13.94%1.98B | 6.82%8.42B | 10.29%6.38B | -2.51%3.45B | 2.45%1.74B | 14.96%7.89B | 7.94%5.79B | 1.41%3.54B |
Cost of sales | ---- | -26.07%-2.65B | ---- | 3.37%-5.05B | ---- | 4.57%-2.1B | ---- | -25.49%-5.23B | ---- | 4.50%-2.2B |
Operating expenses | -14.19%-4.46B | -26.07%-2.65B | -0.23%-1.15B | 3.37%-5.05B | -6.87%-3.91B | 4.57%-2.1B | -15.76%-1.14B | -25.49%-5.23B | -2.56%-3.66B | 4.50%-2.2B |
Gross profit | 46.28%3.62B | 47.03%1.98B | 40.34%834.03M | 26.90%3.37B | 16.17%2.48B | 0.89%1.34B | -16.12%594.29M | -1.34%2.66B | 18.62%2.13B | 12.97%1.33B |
Selling expenses | 8.37%-21.64M | -5.55%-16.09M | 26.36%-5.84M | 5.21%-31.4M | 55.48%-23.61M | 12.55%-15.25M | 37.38%-7.93M | -5.30%-33.13M | -41.40%-53.04M | 31.39%-17.44M |
Administrative expenses | -12.30%-769.35M | -8.89%-622.46M | -8.44%-251.65M | 0.32%-1.3B | 24.63%-685.06M | 11.50%-571.64M | 15.80%-232.06M | 12.67%-1.31B | -13.68%-908.9M | -14.37%-645.92M |
Research and development expenses | 7.79%-197.66M | ---- | -33.52%-61.32M | ---- | ---214.36M | ---- | ---45.93M | ---- | ---- | ---- |
Profit from asset sales | -27.43%34.12K | ---- | ---- | ---- | -3.97%47.01K | ---- | -97.89%2.78K | ---- | -95.52%48.96K | ---- |
Revaluation surplus | 104.22%9.15M | ---- | 258.76%29.93M | ---- | 11.00%-216.7M | ---- | 82.07%-18.86M | ---- | -153.38%-243.48M | ---- |
-Changes in the fair value of other assets | 104.22%9.15M | ---- | 258.76%29.93M | ---- | 11.00%-216.7M | ---- | 82.07%-18.86M | ---- | -153.38%-243.48M | ---- |
Impairment and provision | -410.76%-429.73M | 64.25%-11.46M | -69.87%3.43M | -47.77%-151.06M | -20.20%-84.14M | 41.43%-32.05M | 386.11%11.39M | -28.05%-102.23M | -453.33%-70M | -101.60%-54.73M |
-Other impairment is provision | -410.76%-429.73M | 64.25%-11.46M | -69.87%3.43M | -47.77%-151.06M | -20.20%-84.14M | 41.43%-32.05M | 386.11%11.39M | -28.05%-102.23M | -453.33%-70M | -101.60%-54.73M |
Operating interest expense | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 16.22%-280.27M |
Special items of operating profit | 4.43%47.49M | -428.70%-112.98M | -252.68%-18.32M | -351.42%-152.53M | -81.98%45.48M | 286.91%34.37M | -32.45%12M | 131.03%60.67M | 326.64%252.32M | 69.39%-18.39M |
Operating profit | 79.56%2B | 59.72%1.21B | 73.65%468.47M | 35.95%1.73B | 22.32%1.11B | 140.64%759.84M | -1.15%269.78M | 352.77%1.27B | 25.95%909.15M | 88.47%315.76M |
Financing cost | -5.16%-337.98M | 15.11%-264.21M | 18.14%-92.63M | -13.97%-607.69M | -7.46%-321.39M | ---311.24M | 8.66%-113.15M | ---533.19M | 26.70%-299.08M | ---- |
Share of profits of associates | ---- | 73.21%4.11M | ---- | 139.48%1M | ---- | -28.21%2.37M | ---- | -10,232.00%-2.53M | ---- | 148.12%3.31M |
Share of profit from joint venture company | ---- | ---478K | ---- | ---- | ---- | ---- | ---- | -90.41%7K | ---- | 48.32%-261K |
Special items of earning before tax | -161.05%-67.36M | ---- | -3,542.43%-16.91M | ---- | -78.91%-25.8M | ---- | 108.59%491.18K | ---- | -32.67%-14.42M | ---- |
Earning before tax | 108.07%1.59B | 111.34%953.08M | 128.46%358.93M | 52.40%1.13B | 28.42%764.91M | 41.46%450.98M | 9.62%157.11M | 162.42%739.21M | 96.62%595.64M | 99.05%318.8M |
Tax | -59.88%-362.65M | -164.74%-226.66M | -66.15%-80.24M | -60.94%-288.11M | -25.41%-226.82M | 21.44%-85.62M | -5.36%-48.29M | -97.48%-179.02M | -60.52%-180.86M | -68.40%-108.98M |
After-tax profit from continuing operations | 128.39%1.23B | 98.82%726.42M | 156.11%278.7M | 49.67%838.42M | 29.73%538.09M | 74.13%365.36M | 11.63%108.82M | 193.24%560.19M | 118.00%414.78M | 119.83%209.82M |
Earning after tax | 128.39%1.23B | 98.82%726.42M | 156.11%278.7M | 49.67%838.42M | 29.73%538.09M | 74.13%365.36M | 11.63%108.82M | 193.24%560.19M | 118.00%414.78M | 119.83%209.82M |
Minority profit | 101.58%348.29M | 54.33%173.63M | 466.16%57.32M | -3.95%151.99M | 15.60%172.78M | 10.26%112.5M | -23.35%10.12M | 0.57%158.23M | -3.78%149.46M | 32.04%102.04M |
Profit attributable to shareholders | 141.07%880.64M | 118.62%552.79M | 124.30%221.38M | 70.77%686.43M | 37.69%365.31M | 134.61%252.86M | 17.11%98.7M | 1,092.84%401.95M | 659.78%265.32M | 493.40%107.78M |
Basic earnings per share | 136.36%0.26 | 200.00%0.12 | 133.33%0.07 | 100.00%0.14 | 37.50%0.11 | 33.33%0.04 | 0.00%0.03 | 600.00%0.07 | 700.00%0.08 | 200.00%0.03 |
Diluted earnings per share | 200.00%0.12 | 100.00%0.14 | 33.33%0.04 | 600.00%0.07 | 200.00%0.03 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young | -- | -- | -- | Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.